Company intelligence / Profile preview

Nordic Nanovector ASA

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Nordic Nanovector developed Betalutin®, a first-in-class anti-CD37 antibody-radionuclide conjugate for relapsed/refractory non-Hodgkin lymphoma. After clinical setbacks and discontinuation of its lead program in mid/late-stage trials, the company acquired APIM Therapeutics in late 2022. The combined entity’s main asset became ATX‑101, a peptide targeting PCNA in oncology indications such as ovarian cancer and sarcoma. As of early/mid‑2024, the original pipeline has been deprioritized or discontinued.

Therapeutic areas: Oncology
Modalities: Antibody-radionuclide conjugates (ARCs)Radioimmunotherapy (radio-labeled antibodies)Peptides (via APIM's pipeline post-merger)[7]
Industry: Biotech

Partnerships

Orano Med / AREVA Med – collaboration on Alpha-emitting radioimmunotherapies targeting CD37 for leukemia[8].Thor Medical AS – agreement announced June 2023 regarding radionuclide production capabilities[6].

Beyond the preview

Go deeper on Nordic Nanovector ASA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nordic Nanovector ASA.